

**Table 1. Sociodemographic and clinical features of Venezuelan SLE cohort (n = 406).**

<b>Variable</b>	<b>N (%)</b>
<b>Age (years) mean <math>\pm</math> SD</b>	41.0 $\pm$ 12.2
<b>Female sex</b>	385 (94.83)
<b>Hispanic ethnicity</b>	386 (97.72)
<b>Years of education m <math>\pm</math> SD</b>	11.9 $\pm$ 4.0
<b>Marital status</b>	
<b>Single</b>	196 (48.28)
<b>Married</b>	106 (26.11)
<b>Partner</b>	72 (17.73)
<b>Widowed</b>	11 (2.71)
<b>Divorced</b>	21 (5.7)
<b>Graffar SES</b>	
<b>1 (upper, upper middle)</b>	35 (9.02)
<b>2 (middle)</b>	241 (62.11)
<b>3 (poverty)</b>	112 (28.87)
<b>Current cigarette smoking</b>	60 (14.89)
<b>Current alcohol consumption</b>	113 (27.90)
<b>Disease duration (years), mean <math>\pm</math> SD</b>	10.05 $\pm$ 8.2

<b>Age at disease onset (years), mean ± SD</b>	30.9 ± 11.3
<b>Family history of lupus</b>	72 (18.41)
<b>Hypertension</b>	169 (41.94)
<b>Dyslipidemia</b>	101 (25.06)
<b>Diabetes mellitus</b>	9 (2,23)
<b>1982 ACR criteria</b>	
<b>Malar rash</b>	242 (59.61)
<b>Discoid lupus</b>	73 (18.07)
<b>Photosensitivity</b>	230 (56.79)
<b>Oral ulcers</b>	170 (41.98)
<b>Arthritis</b>	363 (89.41)
<b>Serositis</b>	105 (25.86)
<b>Renal disease*</b>	168 (43.08)
<b>Neurologic disorder</b>	33 (8.42)
<b>Hematologic disorder</b>	163 (40.45)
<b>Immunologic disorder</b>	319 (78.57)
<b>Antinuclear antibody</b>	397 (98.27)
<b>Total number ACR criteria (median, 25%-75% IQR)</b>	5 (5-7)
<b>Lupus subsets</b>	
<b>Lupus nephritis ¶ (n = 353)</b>	117 (33.05)
<b>Neurological § (n = 394)</b>	52 (13.61)
<b>Mucocutaneous (n = 393)</b>	342 (86.80)

<b>Hematological (n = 391)</b>	158 (40.41)
<b>SLEDAI score, mean ± SD</b>	5.22 ± 5.6
<b>SLEDAI active patients *</b>	162 (41.01)
<b>SLICC damage, index mean ± SD</b>	0.87 ± 1.41
<b><i>Current treatment</i></b>	
<b>Oral prednisone</b>	380 (93.6)
<b>Anti-malarials</b>	309 (77.0)
<b>Mofetil mycophenolate</b>	94 (23.4)
<b>Azathioprine</b>	84 (20.9)
<b>NSAID</b>	31 (7.8)
<b>Methotrexate</b>	29 (7.2)
<b>Cyclophosphamide E.V. pulses</b>	19 (4.7)
<b>Methyl prednisolone E.V. pulses</b>	15 (3.7)
<b>Rituximab</b>	5 (1.2)

Note: SLEDAI cut-off for activity  $\geq 6$ ; ACR= American College of Rheumatology; NSAID= Non-steroidal Anti-Inflammatory Drugs; SES= socioeconomic status; SLE= Systemic lupus erythematosus; SLEDAI= Systemic Lupus Erythematosus Disease Activity index; SLICC= Systemic International Collaborating Clinics.

\* Applying the 1982 ACR criteria for SLE classification.

¶ Applying the modified ACR criteria for renal lupus (Dooley et al).

§ Applying the ACR Ad Hoc Committee on neuropsychiatric lupus nomenclature.

**Table 2. Sociodemographic and clinical features in patients by lupus nephritis (N = 353).**

Variables	Lupus nephritis		p-value
	Yes N (%)	No (%)	
<b>Total</b>	117 (33.0)	236 (66.8)	
<b>Age (years) men ± SD</b>	38.41 ± 12.37	42.66 ± 12.07	<b>0.001¶</b>
<b>Female sex</b>	109 (93.16)	228 (96.20)	0.208
<b>Education (years) mean ± SD</b>	11.93 ± 3.81	11.88 ± 3.94	0.5406
<b>Graffar SES</b>			
<b>1</b>	7 (6.14)	26 (11.06)	0.205
<b>2</b>	77 (67.54)	139 (59.15)	
<b>3</b>	30 (26.32)	70 (29.79)	
<b>Marital status</b>			
<b>Single</b>	60 (51.28)	120 (50.63)	0.720
<b>Married/partner</b>	50 (42.74)	96 (40.51)	
<b>Widowed</b>	3 (2.56)	6 (2.53)	
<b>Divorced</b>	4 (3.42)	15 (6.33)	
<b>Family lupus</b>	23 (19.66)	38 (16.24)	0.426
<b>Current cigarette smoking</b>	20 (17.09)	28 (11.97)	0.187
<b>Current alcohol drinking</b>	39 (33.33)	55 (23.31)	<b>0.045</b>
<b>Disease duration (yrs.), mean ± SD</b>	8.80 ± 7.39	10.75 ± 8.46	<b>0.017¶</b>
<b>BMI (Kg/m<sup>2</sup>), mean ± SD</b>	25.03 ± 4.40	25.58 ± 5.15	0.1685
<b>Hypertension</b>	51 (43.59)	94 (40.17)	0.540
<b>Diabetes</b>	3 (2.56)	5 (2.13)	0.796
<b>Dislipidemia</b>	30 (25.86)	57 (24.26)	0.743

<b>Neurolupus</b>	22 (19.82)	28 (12.12)	0.059
<b>Mucocutaneous Lupus</b>	107 (91.45)	202 (85.23)	0.098
<b>Hematological lupus</b>	45 (38.79)	101 (42.62)	0.493
<b>Clinical activity (SLEDAI &gt; 6)</b>	77 (66.96)	67 (29.00)	<b>0.000</b>
<b>Organ damage (SLICC DI &gt;0)</b>	64 (57.14)	82 (36.44)	<b>0.000</b>
<b>Anti-DNA ever</b>	105 (91.30)	61 (25.85)	<b>0.000</b>
<b>Anti-Sm ever</b>	44 (43.56)	73 (33.18)	0.073
<b>Anti-RNP ever</b>	22 (24.18)	48 (24.24)	0.990
<b>Anti-Ro ever</b>	40 (42.11)	65 (31.40)	0.070
<b>Anti-La ever</b>	20 (23.53)	30 (15.15)	0.090
<b>ACA IgG ever</b>	16 (17.39)	24 (12.77)	0.299
<b>ACA IgM ever</b>	9 (9.89)	16 (8.47)	0.695
<b>Anti-β2 GPI IgG</b>	3 (3.45)	7 (3.83)	0.878
<b>Anti-β2 GPI IgM</b>	11 (12.94)	14 (7.73)	0.175
<b>Lupus inhibitor*</b>	2 (2.94)	7 (4.96)	0.500
<b>Current use anti-malarials</b>	92 (78.63)	183 (78.54)	0.984
<b>Current use azathioprine</b>	26 (22.22)	52 (22.22)	1.000
<b>Current use methotrexate</b>	6 (5.13)	17 (7.30)	0.440
<b>Current use MMF</b>	30 (25.64)	51 (21.89)	0.432
<b>Current use oral cyclophosphamide</b>	8 (6.84)	9 (3.85)	0.218
<b>Ever use methylprednisolone pulses</b>	45 (38.46)	59 (25.11)	<b>0.010</b>
<b>Ever use cyclophosphamide pulses</b>	41 (35.04)	57 (24.66)	<b>0.033</b>

Statistical analysis by Pearson Chi square test. ¶ Unpaired Student's t test

\*lupus inhibitor (N = 209); anti-malarials = hydroxychloroquine or chloroquine; BMI= body mass index; DI= damage index; MMF= mycophenolate mofetil; SLEDAI= Systemic Lupus Erythematosus Activity Index; SLICC= Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus; SES= socioeconomic status.

**Table 3. Multivariate logistic regression analysis for lupus nephritis among Venezuelan patients with SLE (n = 353).**

<i>Variable</i>	<i>OR</i>	<i>95% CI</i>	<i>p-value</i>
Age	0.97	0.95 0.98	<b>0.002</b>
Female sex	0.53	0.20 1.43	0.215
<i>Civil status</i>			
Single	Reference		
Married	0.74	0.37 1.50	0.416
Partner	1.00	0.16 5.90	1.000
Widow	1.68	0.78 3.58	0.178
Divorced	0.45	0.10 1.90	0.282
<i>Graffar SES</i>			
Upper, upper middle	Reference		
Middle	1.38	0.62 3.04	0.424
Poverty	0.90	0.37 2.18	0.817
Family history	1.26	0.71 2.23	0.426
Disease duration	0.96	0.94 0.99	<b>0.037</b>
Years of education	1.00	0.94 1.06	0.918
BMI	0.97	0.93 1.02	0.337
Cigarette smoking	1.51	0.81 2.82	0.190
Current alcohol drinking	1.64	1.00 2.68	<b>0.046</b>

Hypertension	1.15	0.73	1.80	0.540
Diabetes	1.21	0.28	5.15	0.796
Dislipidemia	1.08	0.65	1.81	0.743
Neurolupus	2.60	0.68	9.87	0.160
Mucocutaneous lupus	1.85	0.88	3.88	0.102
Hematological lupus	0.85	0.54	1.34	0.493
SLEDAI $\geq$ 6	4.95	3.06	8.026	<b>0.000</b>
SLICC DI (>0)	2.32	1.46	3.69	<b>0.000</b>
Anti-DNA ever	30.12	14.79	61.33	<b>0.000</b>
Anti-Sm	1.55	0.95	2.52	0.074
Anti-RNP	0.99	0.55	1.77	0.990
Anti-Ro	1.58	0.96	2.62	0.071
Anti-La	1.72	0.91	3.24	0.093
Anti-cardiolipin IgG	1.43	0.72	2.86	0.301
Anti-cardiolipin IgM	1.18	0.50	2.79	0.696
Anti- $\beta$ 2 GPI IgG	0.89	0.22	3.55	0.878
Anti- $\beta$ 2 GPI IgM	1.77	0.76	4.09	0.179
Anti-malarials	1.00	0.58	1.72	0.984
Azathioprine	1.00	0.58	1.70	1.000
Methotrexate	0.68	0.26	1.79	0.442
Mofetil mycophenolate	1.23	0.73	2.06	0.433
Cyclophosphamide	1.88	0.68	4.88	0.225

(LR chi2 = 9.56, p = 0.0020)



Note: SES= socioeconomic status; BMI= body mass index; MMF= mycophenolate mofetil; SLEDAI= Systemic Lupus Erythematosus Activity Index; SLICC= Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus; DI= damage index.